AGIO Stock Price, Agios Pharmaceuticals Quote, Chart

Market Summary

USD32.34-0.46

Delayedas of 08 May 2024, 03:03 pm

-1.40%

AGIO Alerts

1 major insider sales recently.

AGIO Stock Price

View Fullscreen

AGIO RSI Chart

AGIO Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

-5.28

Price/Sales (Trailing)

64.36

EV/EBITDA

-4.95

Price/Free Cashflow

-6.18

AGIO Price/Sales (Trailing)

AGIO Profitability

EBT Margin

-1216.91%

Return on Equity

-47.4%

Return on Assets

-41.5%

Free Cashflow Yield

-16.19%

AGIO Fundamentals

AGIO Revenue

Revenue (TTM)

28.9M

Rev. Growth (Yr)

-18.85%

Rev. Growth (Qtr)

-31.19%

AGIO Earnings

Earnings (TTM)

-352.6M

Earnings Growth (Yr)

-0.66%

Earnings Growth (Qtr)

15%

Breaking Down AGIO Revenue

52 Week Range

23.6732.66

(Low)(High)

Last 7 days

0.9%

Last 30 days

19.0%

Last 90 days

38.4%

Trailing 12 Months

29.0%

How does AGIO drawdown profile look like?

AGIO Financial Health

Current Ratio

12.84

AGIO Investor Care

Shares Dilution (1Y)

2.14%

Diluted EPS (TTM)

-6.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	28.9M	0	0	0
2023	19.7M	26.1M	30.0M	28.8M
2022	85.0M	45.6M	6.3M	12.3M
2021	0	163.8M	124.4M	0
2020	174.8M	184.3M	193.7M	203.2M
2019	115.9M	101.7M	112.5M	117.9M
2018	41.3M	70.3M	74.2M	94.4M
2017	49.1M	53.5M	55.9M	43.0M
2016	70.7M	64.5M	68.0M	69.9M
2015	62.0M	66.9M	38.4M	44.6M
2014	27.7M	29.8M	57.5M	65.4M
2013	25.1M	25.1M	25.1M	25.5M
2012	22.7M	23.5M	24.3M	25.1M
2011	0	0	0	21.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Agios Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	fouse jacqualyn a	sold	-214,642	27.55	-7,791	-
Apr 08, 2024	fouse jacqualyn a	acquired	-	-	15,934	-
Mar 07, 2024	foster-cheek kaye i	sold	-40,631	31.62	-1,285	-
Mar 06, 2024	foster-cheek kaye i	sold	-141,236	31.99	-4,415	-
Mar 05, 2024	burns james william	sold	-86,049	32.57	-2,642	chief legal officer
Mar 05, 2024	goff brian	sold	-135,361	32.57	-4,156	chief executive officer
Mar 05, 2024	washburn theodore james jr.	sold	-39,540	32.57	-1,214	principal accounting officer
Mar 05, 2024	jones cecilia	sold	-21,887	32.57	-672	chief financial officer
Mar 05, 2024	washburn theodore james jr.	sold	-60,737	31.75	-1,913	principal accounting officer
Mar 05, 2024	foster-cheek kaye i	sold	-9,663	32.21	-300	-

Which funds bought or sold AGIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	DiNuzzo Private Wealth, Inc.	sold off	-100	-23.00	-	-%
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	reduced	-3.54	77,000	364,000	-%
May 06, 2024	SG Americas Securities, LLC	sold off	-100	-555,000	-	-%
May 06, 2024	Advisory Services Network, LLC	sold off	-100	-7,795	-	-%
May 03, 2024	Riggs Asset Managment Co. Inc.	new	-	1,199	1,199	-%
May 03, 2024	SIGNATUREFD, LLC	reduced	-28.86	-1,018	14,415	-%
May 03, 2024	Glassman Wealth Services	sold off	-100	-2,227	-	-%
May 03, 2024	GSA CAPITAL PARTNERS LLP	reduced	-70.37	-1,417,000	902,000	0.07%
May 03, 2024	VICTORY CAPITAL MANAGEMENT INC	new	-	210,820	210,820	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	added	5.47	6,426	23,129	-%

Are Funds Buying or Selling AGIO?

Are funds buying AGIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGIO

No. of Funds

AGIO Alerts

1 major insider sales recently.

Unveiling Agios Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	6.31%	3,524,000	SC 13G/A
Feb 14, 2024	rock springs capital management lp	3.85%	2,152,173	SC 13G/A
Feb 13, 2024	bb biotech ag	7.2%	4e+06	SC 13G/A
Feb 12, 2024	vanguard group inc	10.02%	5,599,917	SC 13G/A
Feb 12, 2024	vanguard group inc	9.89%	5,527,438	SC 13G/A
Feb 08, 2024	farallon capital partners, l.p.	0.6%	350,343	SC 13G/A
Jan 25, 2024	blackrock inc.	8.9%	4,962,237	SC 13G/A
Jan 22, 2024	state street corp	4.70%	2,625,685	SC 13G/A
Nov 09, 2023	farallon capital partners, l.p.	0.6%	332,366	SC 13G
Nov 09, 2023	wellington management group llp	3.95%	2,200,757	SC 13G/A

Recent SEC filings of Agios Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 10, 2024	4	Insider Trading
Mar 11, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Agios Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Agios Pharmaceuticals Inc News

Latest updates

Agios Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	60.9%	8,189,000	5,091,000	7,399,000	8,254,000	8,091,000	6,273,500	3,516,000	1,793,000	694,000	256,000	22,150,500	44,045,000	1,115,000	44,106,500	87,098,000	35,440,000	26,024,000	26,221,000	30,227,000	30,013,000	15,198,000
Costs and Expenses	-11.6%	100,261,000	113,380,000	108,296,000	100,412,000	96,222,000	103,482,000	94,606,000	103,222,000	101,977,000	91,152,000	91,222,000	85,332,000	80,290,000	83,264,000	87,030,000	-86,607,000	135,084,000	140,082,000	127,710,000	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	135,084,000	140,082,000	127,710,000	126,369,000	114,360,000
S&GA Expenses	-12.2%	31,014,000	35,305,000	25,822,000	30,409,000	28,367,000	32,771,000	29,123,000	28,264,000	31,515,000	27,152,000	29,215,000	25,908,500	28,347,000	29,178,000	31,672,000	4,807,000	33,019,000	32,390,000	31,791,000	31,858,000	31,104,000
R&D Expenses	-11.4%	68,620,000	77,489,000	81,841,000	68,895,000	67,301,000	70,298,000	64,966,000	74,523,000	70,123,000	64,000,000	62,007,000	59,423,500	51,943,000	54,086,000	55,358,000	-90,384,000	101,672,000	107,389,000	95,585,000	93,809,000	82,561,000
EBITDA Margin	0.3%	-12.17	-12.21	-7.42	-8.53	-11.33	-18.15	-55.53	-7.61	-4.09	-2.68	-2.00	-	-	-	-	-	-	-	-	-	-
Income Taxes	-2988.2%	-525,000	-17,000	785,000	801,000	-	-1,940,000	98,000	-	1,842,000	2,716,000	6,200,000	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	33,832,000	-	-	-	-84,259,000	-82,790,000	-84,541,000	-79,175,000	-81,495,000	-84,094,000	-	-	-	-	-	-
EBT Margin	0.3%	-12.17	-12.21	-7.72	-8.87	-11.78	-18.88	-56.96	-7.81	-4.19	-2.75	-2.06	-	-	-	-	-	-	-	-	-	-
Net Income	15.0%	-81,549,000	-95,940,000	-91,324,000	-83,806,000	-81,018,000	36,526,000	-81,747,000	-91,806,000	-94,774,000	-88,766,000	-86,217,000	-97,657,000	-98,979,000	-90,478,000	-40,256,000	-102,350,000	-106,173,000	-109,871,000	-93,078,000	-91,794,000	-94,664,000
Net Income Margin	0.2%	-12.19	-12.21	-7.32	-8.04	-11.08	-18.88	-57.99	-8.11	-4.29	12.87	9.72	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-37.5%	-100,008,000	-72,722,000	-62,012,000	-66,745,000	-95,582,000	-66,276,000	-71,389,000	-76,155,000	-100,539,000	-85,162,000	-117,543,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.3%	850	937	1,007	1,085	1,151	1,239	1,180	1,252	1,336	1,438	1,541	1,875	2,488	853	908	976	800	891	699	784	822
Current Assets	-20.4%	664	834	704	757	792	833	785	870	975	1,064	1,305	1,703	2,355	637	669	846	587	612	490	534	557
Cash Equivalents	34.6%	119	88.00	64.00	85.00	104	139	122	89.00	80.00	203	400	969	1,888	127	105	296	89.00	81.00	82.00	84.00	103
Inventory	20.9%	23.00	19.00	17.00	16.00	11.00	8.00	5.00	4.00	2.00	-	-	-	-	15.00	11.00	11.00	10.00	7.00	6.00	5.00	2.00
Net PPE	-8.2%	14.00	15.00	17.00	20.00	21.00	23.00	25.00	27.00	29.00	29.00	25.00	27.00	29.00	31.00	33.00	34.00	34.00	31.00	24.00	23.00	24.00
Liabilities	-16.1%	106	126	120	121	115	138	130	128	128	146	147	153	192	453	428	418	174	250	250	251	202
Current Liabilities	-23.9%	52.00	68.00	58.00	55.00	45.00	63.00	54.00	48.00	46.00	60.00	58.00	61.00	97.00	94.00	70.00	64.00	70.00	93.00	92.00	90.00	81.00
Shareholder's Equity	-8.3%	744	811	887	964	1,037	1,101	1,050	1,124	1,207	1,292	1,395	1,722	2,297	400	480	558	625	641	448	533	620
Retained Earnings	-9.9%	-904	-822	-726	-635	-551	-470	-507	-425	-333	-238	-144	-55.37	31.00	-1,843	-1,745	-1,646	-1,556	-1,516	-1,413	-1,307	-1,197
Additional Paid-In Capital	0.6%	2,452	2,437	2,422	2,411	2,399	2,386	2,375	2,362	2,351	2,334	2,322	2,306	2,266	2,243	2,226	2,204	2,182	2,156	1,862	1,840	1,818
Shares Outstanding	1.4%	57.00	56.00	56.00	56.00	56.00	55.00	55.00	55.00	55.00	60.00	57.00	61.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,558	-	-	-	1,200	-	-	-	3,268	-	-	-	3,280	-	-	-	2,563	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-37.8%	-99,867	-72,488	-61,643	-66,748	-95,183	-66,163	-71,351	-74,229	-97,735	-84,093	-85,184	-117,294	-120,749	-49,397	-68,207	-67,797	-105,358	-93,611	-85,589	-88,151	-103,271
Share Based Compensation	-33.2%	9,234	13,814	9,076	11,737	10,139	11,465	11,156	11,165	15,510	11,621	12,148	14,885	14,854	13,341	14,977	17,614	15,670	2,807	18,588	18,547	18,108
Cashflow From Investing	30.4%	124,562	95,513	39,341	47,125	57,596	82,951	104,070	82,813	-26,573	-94,419	-232,731	-298,149	1,874,077	71,396	-126,244	22,459	108,135	-184,773	80,381	64,480	131,352
Cashflow From Financing	592.3%	5,864	847	1,882	237	2,467	22.00	1,187	-67.00	1,208	-18,586	-250,985	-503,458	7,261	582	3,448	252,103	5,385	277,606	3,337	3,808	4,860
Buy Backs	-	-	-	-	-	-	-	-	-	-	19,048	254,391	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AGIO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenue	$ 8,189	$ 5,609
Operating expenses:
Cost of sales	627	554
Research and development	68,620	67,301
Selling, general and administrative	31,014	28,367
Total operating expenses	100,261	96,222
Loss from operations	(92,072)	(90,613)
Interest income, net	8,889	8,091
Other income, net	1,634	1,504
Net loss	$ (81,549)	$ (81,018)
Net loss per share - basic (in usd per share)	$ (1.45)	$ (1.47)
Net loss per share - diluted (in usd per share)	$ (1.45)	$ (1.47)
Weighted-average number of common shares used in computing net loss per share - basic (in shares)	56,383,475	55,265,390
Weighted-average number of common shares used in computing net loss per share – diluted (in shares)	56,383,475	55,265,390
Product revenue, net
Revenues:
Total revenue	$ 8,189	$ 5,609

AGIO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 118,764	$ 88,205
Marketable securities	479,227	688,723
Accounts receivable, net	3,453	2,810
Inventory	23,070	19,076
Prepaid expenses and other current assets	39,113	35,021
Total current assets	663,627	833,835
Marketable securities	116,301	29,435
Operating lease assets	51,606	54,409
Property and equipment, net	14,119	15,382
Other non-current assets	4,056	4,057
Total assets	849,709	937,118
Current liabilities:
Accounts payable	11,155	9,780
Accrued expenses	25,129	43,167
Operating lease liabilities	15,407	15,008
Total current liabilities	51,691	67,955
Operating lease liabilities, net of current portion	52,940	56,988
Other non-current liabilities	1,156	1,156
Total liabilities	105,787	126,099
Stockholders’ equity:
Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 125,000,000 shares authorized; 72,967,922 shares issued and 56,751,511 shares outstanding at March 31, 2024, and 72,161,489 shares issued and 55,945,078 shares outstanding at December 31, 2023	73	72
Additional paid-in capital	2,451,620	2,436,523
Accumulated other comprehensive loss	(1,087)	(441)
Treasury stock, at cost (16,216,411 shares at March 31, 2024 and December 31, 2023)	(802,486)	(802,486)
Accumulated deficit	(904,198)	(822,649)
Total stockholders’ equity	743,922	811,019
Total liabilities and stockholders’ equity	$ 849,709	$ 937,118

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Brian M. Goff M.B.A.
WEBSITE	agios.com
INDUSTRY	Biotechnology
EMPLOYEES	389

Agios Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Agios Pharmaceuticals Inc? What does AGIO stand for in stocks?

AGIO is the stock ticker symbol of Agios Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agios Pharmaceuticals Inc (AGIO)?

As of Tue May 07 2024, market cap of Agios Pharmaceuticals Inc is 1.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers. The fair value of Agios Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agios Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agios Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AGIO is over valued or under valued. Whether Agios Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Agios Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGIO.

What is Agios Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, AGIO's PE ratio (Price to Earnings) is -5.28 and Price to Sales (PS) ratio is 64.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agios Pharmaceuticals Inc's stock?

In the past 10 years, Agios Pharmaceuticals Inc has provided -0.011 (multiply by 100 for percentage) rate of return.